RemeGen Co. Ltd. Class A
688331
Classement en actions
#2421
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces,... RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of gastric cancer, urothelial carcinoma, breast cancer, and other tumors. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF); RC88, an antibody-drug conjugate (ADC) that targets mesothelin; and RC148, a bispecific antibody ADC drug that in Phase1/2 clinical studies targeting program cell death protein 1 (PD-1) and VEGF; RC278, an ADC drug for the treatment of multiple solid tumors; and RC288, a dual-antibody ADC drug for the treatment of various tumors. The company was founded in 2008 and is headquartered in Yantai, the People's Republic of China.
Prix de l'action
$14.49
Capitalisation boursière
$8.11B
Changement (1 jour)
2.99%
Changement (1 an)
9.18%
Pays
CN
Échange RemeGen Co. Ltd. Class A (688331)
Catégorie
Healthcare
Bénéfices pour RemeGen Co. Ltd. Class A (688331)
Bénéfices en Jun 2026 TTM : $843.65M
Selon les derniers rapports financiers de RemeGen Co. Ltd. Class A, les bénéfices actuels de l'entreprise sont de $843.65M. En 2023, l'entreprise a réalisé un bénéfice de $-213.49M, une diminution par rapport à celui de 2022 qui était de $-144.80M. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour RemeGen Co. Ltd. Class A de 2018 à 2026
Bénéfices à la fin de chaque année
| Année | Bénéfices | Changez |
|---|---|---|
| 2026 (TTM) | $843.65M | -519.37% |
| 2024 | $-201.17M | -5.77% |
| 2023 | $-213.49M | 47.44% |
| 2022 | $-144.80M | -433.15% |
| 2021 | $43.46M | -140.69% |
| 2020 | $-106.82M | 72.87% |
| 2019 | $-61.79M | 57.45% |
| 2018 | $-39.24M | 0.00% |
Bénéfices des entreprises similaires ou concurrentes
| Entreprise | Bénéfices | Différence de bénéfices | Pays |
|---|---|---|---|
| $5.27B | 525.25% |
US
|
|
| $-3.09B | -465.91% |
US
|
|
| $-4.02B | -576.05% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 131.22% |
NL
|
